8-K current report · filed Oct 29, 2026

Kymera Therapeutics, Inc. (KYMR) 8-K Current Report: October 29, 2026

Item 2.02Item EX-99.1KYMR overview

Short answer

Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results announced for period ended September 30, 2026.

Kymera Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Quarterly results announced for period ended September 30, 2026
  • Full financial details and management commentary in Exhibit 99.1
  • Information furnished under Regulation FD, limiting Section 18 liability absent specific incorporation by reference

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 net loss $132.0M, or $1.32 per share, versus $82.2M, reflecting sharply higher pipeline investment
  • R&D expense $128.5M, up from $74.1M, primarily supporting STAT6, discovery programs and organizational growth
  • KT-579 achieved ≥90% median IRF5 degradation and biomarker suppression of 88%-98%, supporting lupus Phase 1b launch by early 2027
  • KT-621 BROADEN2 AD topline data expected by year-end 2026, with Phase 3 initiation targeted for mid-2027
  • Cash, equivalents and investments $1.6B, providing runway into 2029 across multiple clinical inflection points

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Kymera Therapeutics, Inc. 8-K filings

Get the next KYMR 8-K as it lands

Follow KYMR for push alerts, or ask the research agent what this filing means.